Barclays Double Downgrades Cellectis (CLLS) to Underweight

September 16, 2026 3:49 AM

Barclays analyst Lukas Shumway downgraded Cellectis (NASDAQ: CLLS) from Overweight to Underweight with a price target of $1.30 (from $9.00).The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found